

BIOCON GROUP

FACT SHEET

March - 2019

BIOCON LIMITED (CONSOLIDATED)
BALANCE SHEET

(Rs Cr)

	March 31, 2019	March 31, 2018
ASSETS		
Non-current assets		
(a) Property, plant and equipment	4,253	3,630
(b) Capital work-in-progress	1,287	779
(c) Goodwill	26	26
(d) Other intangible assets	192	43
(e) Intangible assets under development	612	524
(f) Investments in associates and a joint venture	43	64
(g) Financial assets		
Investments	139	-
Derivative assets	71	111
Other financial assets	39	25
(h) Income tax asset, net	169	127
(i) Deferred tax asset, net	325	193
(j) Other non-current assets	213	319
	7,370	5,841
Current assets		
(a) Inventories	1,032	723
(b) Financial assets		
Investments	829	611
Trade receivables	1,292	1,064
Cash and cash equivalents	730	501
Other bank balances	327	822
Derivative assets	78	99
Other financial assets	387	192
(c) Other current assets	149	137
	4,823	4,149
TOTAL	12,192	9,990
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	300	300
(b) Other equity	5,798	4,881
Equity attributable to owners of the Company	6,098	5,181
Non-controlling interests	609	468
	6,707	5,649
Non-current liabilities		
(a) Financial liabilities		
Borrowings	1,542	1,790
Derivative liability	35	18
Other financial liabilities	-	-
(b) Provisions	66	49
(c) Other non-current liabilities	805	342
	2,448	2,199
Current liabilities		
(a) Financial liabilities		
Borrowings	261	130
Trade payables	1,198	1,006
Derivative liability	14	6
Other financial liabilities	991	556
(b) Provisions	81	47
(c) Income tax liability, net	124	89
(d) Other current liabilities	369	308
	3,038	2,142
TOTAL	12,192	9,990

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	12M FY 2019	12M FY 2018	Variance
INCOME			
Small molecules	1,773	1,508	18%
Biologics	1,517	770	97%
Branded formulations	656	612	7%
Research services	1,826	1,423	28%
Inter-segment	(257)	(183)	41%
Revenue from operations #	5,514	4,130	34%
Other income	144	206	-30%
TOTAL REVENUE	5,659	4,336	31%
EXPENDITURE			
Material & Power costs	2,136	1,825	17%
Staff costs	1,062	846	26%
Research & Development expenses*	290	216	34%
Other expenses	633	414	53%
Manufacturing, staff & other expenses	4,121	3,301	25%
EBITDA	1,538	1,035	49%
Interest & Finance charges	71	61	15%
Depreciation & Amortisation	448	385	16%
Share of profit in JV / Associate, net	(1)	(21)	-96%
PBT BEFORE EXCEPTIONAL ITEM	1,020	610	67%
Exceptional item, Net	195	-	-
PBT	1,215	610	99%
Taxes	194	157	24%
Taxes on exceptional item	18	-	-
NET PROFIT BEFORE MINORITY INTEREST	1,003	453	121%
Minority interest	97	81	21%
NET PROFIT FOR THE PERIOD	905	372	143%
EPS Rs.	15.1	6.2	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	25	23	
* Gross Research & Development expenses	480	380	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q4 FY 19	Q4 FY 18	Variance
INCOME			
Small molecules	472	426	11%
Biologics	451	241	87%
Branded formulations	133	149	-11%
Research services	534	409	30%
Inter-segment	(61)	(55)	11%
Revenue from operations #	1,529	1,170	31%
Other income	28	67	-58%
TOTAL REVENUE	1,557	1,237	26%
EXPENDITURE			
Material & Power costs	549	523	5%
Staff costs	293	234	25%
Research & Development expenses*	92	51	81%
Other expenses	192	129	49%
Manufacturing, staff & other expenses	1,126	937	20%
EBITDA	431	300	43%
Interest & Finance charges	16	17	-6%
Depreciation & Amortisation	120	95	26%
Share of profit in JV / Associate, net	11	(5)	-320%
PBT BEFORE EXCEPTIONAL ITEM	284	193	47%
Exceptional item, Net	-	-	-
PBT	284	193	47%
Taxes	41	41	0%
Taxes on exceptional item	-	-	-
NET PROFIT BEFORE MINORITY INTEREST	243	152	59%
Minority interest	29	22	33%
NET PROFIT FOR THE PERIOD	214	130	64%
EPS Rs.	3.6	2.2	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	7	2	
* Gross Research & Development expenses	166	98	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q4 FY 19	Q3 FY 19	Variance
INCOME			
Small molecules	472	469	1%
Biologics	451	449	1%
Branded formulations	133	212	-37%
Research services	534	467	14%
Inter-segment	(61)	(56)	9%
Revenue from operations #	1,529	1,541	-1%
Other income	28	25	10%
TOTAL REVENUE	1,557	1,566	-1%
EXPENDITURE			
Material & Power costs	549	590	-7%
Staff costs	293	269	9%
Research & Development expenses*	92	77	20%
Other expenses	192	224	-14%
Manufacturing, staff & other expenses	1,126	1,160	-3%
EBITDA	431	406	6%
Interest & Finance charges	16	19	-15%
Depreciation & Amortisation	120	117	3%
Share of profit in JV / Associate, net	11	(13)	-190%
PBT BEFORE EXCEPTIONAL ITEM	284	283	0%
Exceptional item, Net	-	6	-
PBT	284	289	-2%
Taxes	41	46	-11%
Taxes on exceptional item	-	-	-100%
NET PROFIT BEFORE MINORITY INTEREST	243	243	0%
Minority interest	29	26	14%
NET PROFIT FOR THE PERIOD	214	217	-1%
EPS Rs.	3.6	5.9	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	7	7	
* Gross Research & Development expenses	166	120	